Study examines drug regimen for the treatment of non-small cell lung cancer among older patients
Analysis of a drug regimen approved by the F.D.A. in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients age 65 years and older who received this regimen did not have improved survival compared to patients who received the standard treatment of carboplatin and paclitaxel alone, according to a study in the April 18 issue of JAMA, a theme issue on comparative effectiveness research.
Deborah Schrag, M.D., M.P.H., of the Dana-Farber Cancer Institute, Boston, presented the findings of the study at a JAMA media briefing at the National Press Club.
"A previous randomized trial demonstrated that adding bevacizumab to carboplatin and paclitaxel improved survival in advanced non-small cell lung cancer (NSCLC). However, longer survival was not observed in the subgroup of patients aged 65 years or older, " according to background information in the article. "Notwithstanding the uncertainty about benefits in the population aged 65 years or older, the Centers for Medicare & Medicaid Services (CMS) has covered bevacizumab therapy for its enrollees subsequent to Food and Drug Administration [FDA] approval. Little is known about how clinicians have interpreted efficacy studies to formulate treatment recommendations, and given that approximately two-thirds of patients with lung cancer receive their diagnoses at age 65 years or older, establishing the survival advantage of bevacizumab in the Medicare population is a priority for informed decision making."
Dr. Schrag and colleagues conducted a study to examine whether adding bevacizumab to carboplatin-paclitaxel was associated with improved survival in the Medicare population. The researchers used analytic strategies to address confounding (factors that can influence outcomes) and selection bias caused by the lack of treatment randomization in observational studies that may limit the ability to make valid inferences about causality. The study included 4,168 Medicare beneficiaries ages 65 years or older with advanced (stage IIIB or stage IV) non-squamous cell NSCLC diagnosed in 2002-2007. Patients were categorized into 3 cohorts based on diagnosis year and type of initial chemotherapy administered within 4 months of diagnosis: (1) diagnosis in 2006-2007 and bevacizumab-carboplatin-paclitaxel therapy; (2) diagnosis in 2006-2007 and carboplatin-paclitaxel therapy; or (3) diagnosis in 2002-2005 and carboplatin-paclitaxel therapy. The associations between carboplatin-paclitaxel with vs. without bevacizumab and overall survival were compared using various models and analyses.
The researchers found that the median (midpoint) overall survival was 9.7 months for patients receiving the bevacizumab combination compared with 8.9 months for those receiving carboplatin-paclitaxel in 2006-2007, and 8.0 months for those receiving carboplatin-paclitaxel in 2002-2005. The 1-year survival probabilities were 39.6 percent for bevacizumab-carboplatin-paclitaxel vs. 40.1 percent for carboplatin-paclitaxel in 2006-2007 and 35.6 percent for carboplatin-paclitaxel in 2002-2005. Controlling for demographic and clinical characteristics in adjusted models, the authors did not find a significant difference in overall survival between patients treated with bevacizumab and those treated only with carboplatin-paclitaxel in either 2006-2007 or 2002-2005.
None of the 4 propensity score-adjusted models demonstrated any evidence to support the superiority of bevacizumab-carboplatin-paclitaxel to carboplatin-paclitaxel. Also, neither subgroup nor sensitivity analyses changed their finding that bevacizumab was not associated with a survival advantage.
"In the future, for malignancies like NSCLC that disproportionately affect elderly patients or where the CMS covers a large proportion of treatment costs, negotiations with pharmaceutical sponsors of pivotal trials might mandate adequate representation of elderly patients and/or preplanned subgroup analyses relevant to the Medicare population. Absent this information, clinicians will need to rely on efficacy data from subgroup analysis of randomized trials, observational data such as this report, and their clinical judgment to make treatment recommendations. Given that neither subgroup analyses from efficacy studies nor observational data analyses identify a benefit for adding bevacizumab to standard carboplatin-paclitaxel therapy, bevacizumab should not be considered standard of care in this context. Clinicians should exercise caution in making treatment recommendations and should use bevacizumab judiciously for their older patients," the authors conclude.
More information: JAMA. 2012;307:1593-1601.
Provided by JAMA and Archives Journals
- Adding ipilimumab to standard chemotherapy treatment for late-stage lung cancer may improve survival Dec 09, 2010 | not rated yet | 0
- Drug combination may provide option to patients with NSCLC ineligible for bevacizumab Apr 03, 2012 | not rated yet | 0
- Novel paclitaxel formulation encouraging for treating advanced lung cancer Jun 15, 2010 | not rated yet | 0
- Novel 4-drug combination proves safe for lung cancer treatment Nov 13, 2008 | not rated yet | 0
- Adding topotecan to standard treatment for ovarian cancer does not improve progression-free survival Oct 11, 2010 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
In a new study described in the journal Oncogene, researchers reveal how a key player in cell growth, immunity and the inflammatory response can be transformed into a primary contributor to tumor growth.
Cancer 2 hours ago | not rated yet | 0 |
A new study conducted using extensive medical records of over one million Israeli adolescents before military service shows clearly how exposure to the Israeli sun of young, light-skinned children increases substantially ...
Cancer 4 hours ago | not rated yet | 0
A new measure of the heterogeneity – the variety of genetic mutations – of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue ...
Cancer 8 hours ago | not rated yet | 0
Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis—two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic ...
Cancer 9 hours ago | not rated yet | 0
The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...
Cancer May 19, 2013 | not rated yet | 0
A new study conducted by researchers at the Child Study Center at NYU Langone Medical Center found men diagnosed as children with attention-deficit/hyperactivity disorder (ADHD) were twice as likely to be obese in a 33-year ...
26 minutes ago | not rated yet | 0 |
A new computer model could help scientists predict when a particular strain of avian influenza might become infectious from bird to human, according to a report to be published in the International Journal Data Mining an ...
54 minutes ago | not rated yet | 0
Researchers at Lund University in Sweden have mapped the significance of heredity for common forms of atherosclerotic disease. No studies have previously examined whether different forms of the disease share heredity.
51 minutes ago | not rated yet | 0
A novel vaccine study from South Dakota State University (SDSU) will headline the groundbreaking research that will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference ...
3 minutes ago | not rated yet | 0
Parkinson's disease (PD) is a degenerative neurological disorder marked by a progressive loss of motor control. Despite intensive research, there are currently no approved therapies that have been demonstrated to alter the ...
3 minutes ago | not rated yet | 0
It is impossible to predict the evolution of China's human H7N9 bird flu outbreak as researchers are still trying to understand the source of human transmission, the head of the World Health Organisation said Monday.
33 minutes ago | not rated yet | 0